Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.
byBenzinga Newsdesk
December 22, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why SunPower Stock Is Down Today

By Erica Kollmann
February 16, 5:00 PM
On Thursday, SunPower announced fourth-quarter losses of 51 cents per share which missed the analyst consensus estimate of losses of 24 cents by 112.5%. The company reported quarterly sales of $361.3 million, missing the analyst consensus estimate of $362.85 million and respresting a 27.35% decrease over sales of $497.31 million from the same period last year.

SPWR